Vraylar Does Not Cause Hypocalcemia
Based on the FDA drug label and available evidence, Vraylar (cariprazine) does not cause hypocalcemia. The official FDA prescribing information lists hyponatremia as a rare metabolic/nutrition disorder but makes no mention of hypocalcemia as an adverse effect 1.
Key Evidence from FDA Drug Label
The comprehensive adverse reaction profile from clinical trials involving 5,763 patients treated with Vraylar documented the following metabolic abnormalities 1:
- Metabolism and Nutrition Disorders: Decreased appetite (frequent), hyponatremia (rare)
- No hypocalcemia reported in any frequency category (frequent, infrequent, or rare)
- Laboratory monitoring focused on transaminases and creatine phosphokinase elevations, not calcium levels
Important Clinical Context
The guidelines discussing hypocalcemia in the provided evidence relate to antipsychotic medications as a class in specific populations, not Vraylar specifically:
- Patients with 22q11.2 deletion syndrome have underlying parathyroid dysfunction and may develop hypocalcemia when exposed to biological stressors, including antipsychotic medications 2
- This represents a patient-specific vulnerability rather than a drug-specific effect
- In these patients, hypocalcemia can be precipitated by "medications (including antipsychotics)" due to their underlying syndrome, not as a direct pharmacologic effect of the antipsychotic 2
Clinical Implications
For routine clinical practice: Calcium monitoring is not indicated when prescribing Vraylar unless the patient has specific risk factors unrelated to the medication itself (e.g., 22q11.2 deletion syndrome, hypoparathyroidism, post-surgical states).
For special populations: If prescribing Vraylar to patients with known parathyroid dysfunction or 22q11.2 deletion syndrome, monitor calcium levels as you would with any biological stressor, not because Vraylar specifically causes hypocalcemia 2.
The metabolic profile of Vraylar has been extensively studied, showing neutral effects on weight and metabolic parameters 3, 4, with no signal for calcium disturbances in real-world or clinical trial data.